Q-omics provides the consensus-scored TRAJ10 profile across patient tissues and cancer cell-line models. TRAJ10 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, TRAJ10 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, TRAJ10 RNA expression shows 12,357 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, KIRC, and LSCC as cancer lineages where TRAJ10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ10 survival associations across molecular data types. TRAJ10 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ10 RNA expression–survival associations across cancer types. High TRAJ10 expression shows unfavorable associations in KICH, MESO and THYM, but favorable associations in ESCA, CESC and LUAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for TRAJ10 RNA expression.
This table summarizes TRAJ10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ10 shows lower tumor expression in THCA and higher tumor expression in KIRC and BRCA. The KIRC box plot shows higher TRAJ10 RNA expression in tumor versus normal tissue (log2 FC = +0.287, t-test p < 0.001).
This table shows molecular features associated with TRAJ10 in patient tissues and cancer cell lines. In patient samples, TRAJ10 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
